Provided by Tiger Trade Technology Pte. Ltd.

Bioventus Inc.

14.02
-0.3600-2.50%
Post-market: 14.020.00000.00%19:30 EDT
Volume:669.50K
Turnover:9.44M
Market Cap:1.18B
PE:17.93
High:14.55
Open:14.42
Low:13.93
Close:14.38
52wk High:15.89
52wk Low:6.26
Shares:84.09M
Float Shares:33.47M
Volume Ratio:1.06
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7821
EPS(LYR):0.3300
ROE:25.68%
ROA:5.49%
PB:5.16
PE(LYR):42.48

Loading ...

Bioventus Shareholders Back Directors and Auditor at 2026 Meeting

TIPRANKS
·
Jun 04

Bioventus holds annual shareholder meeting, elects directors

Reuters
·
Jun 04

Bioventus CFO to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 02

Bravura Solutions Updates Registered Office Location in Sydney

TIPRANKS
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Bioventus (BVS) and Elanco Animal Health (ELAN)

TIPRANKS
·
May 24

Bioventus Is Maintained at Outperform by Barrington Research

Dow Jones
·
May 22

Bioventus Affirms Outlook After FDA Device Reclassification

TIPRANKS
·
May 22

Bioventus Inc - Reiterates 2026 Financial Guidance - SEC Filing

THOMSON REUTERS
·
May 22

Bioventus Inc - CMS Updates Medicare Fee Schedule for Non-Invasive Bone Growth Stimulators Effective May 18, 2026 - SEC Filing

THOMSON REUTERS
·
May 22

Bioventus Inc - Does Not Expect Material Impact From Exogen Reimbursement Changes in FY2026 - SEC Filing

THOMSON REUTERS
·
May 22

Bioventus Inc - FDA Reclassifies Exogen Ultrasound Bone Healing System to Class Ii Device on April 16, 2026 - SEC Filing

THOMSON REUTERS
·
May 22

FDA reclassifies Bioventus Exogen bone stimulator, CMS updates Medicare billing rules

Reuters
·
May 22

Bioventus Down Nearly 9%, On Pace for Largest Percent Decrease Since May 2025 -- Data Talk

Dow Jones
·
May 21

Bravura Names Group CEO Colin Greenhill to Board as Executive Director

TIPRANKS
·
May 11

Bioventus Reiterated at Buy as Strong FY26 Start, Deleveraging, and Discount Valuation Support Unchanged $15 Price Target

TIPRANKS
·
May 07

Bioventus Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

Bioventus Q1 returns to profit; revenue rises 7% to $132.1 million

Reuters
·
May 06

BRIEF-Bioventus Q1 Sales USD 132.1 Million Vs. IBES Estimate USD 129.8 Million

Reuters
·
May 06

Bioventus Inc - Sees 2026 Cash From Operations $84 Mln-$89 Mln, up $2 Mln From Prior Guidance

THOMSON REUTERS
·
May 06

Bioventus Inc - Sees 2026 Adj EPS $0.75-$0.79, up $0.02 From Prior Guidance

THOMSON REUTERS
·
May 06